The Board of Directors of Aurobindo Pharma Limited, in its meeting held on May 21, 2026, approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The company reported a strong performance in its consolidated financial results, with revenue from operations for the quarter ended March 31, 2026, reaching INR 88,533.4 million, compared to INR 86,459.0 million in the previous quarter and INR 83,821.2 million in the corresponding quarter of the previous year. The consolidated profit after tax for the quarter ended March 31, 2026, stood at INR 19,459.1 million (derived from Consolidated Revenue of INR 88,533.4 million, Total Expenses of INR 67,614.9 million, and corresponding tax/exceptional items noted in the financial annexures), reflecting growth compared to previous periods.

Table: Financial Result Analysis (Consolidated)

(Note: Profit After Tax derived from comprehensive consolidated data for the quarter. Percentages are calculated based on reported figures for the respective quarters.)

Aurobindo Pharma Limited is a leading global pharmaceutical company headquartered in Hyderabad, India. Established in 1986, it operates 29 manufacturing facilities across the globe, producing a vast portfolio of products, including generic drugs, over-the-counter medications, and high-quality biosimilars, with a strong focus on oncology and immunology therapeutic segments. The company markets its products in over 125 countries and maintains a robust research and development pipeline, further strengthened by various strategic supply pacts and acquisitions aimed at expanding its biologics manufacturing capabilities. As of early 2026, the company continues to see strong institutional interest, with significant holdings from foreign institutional investors (FIIs) and major domestic mutual funds.